Ask AI
ProCE Banner Activity

Identification and Management of Adverse Events With TROP-2–Targeted ADCs

Slideset

Matthew Gubens, MD, MS, FASCO, reviews key toxicities with TROP-2–targeted ADCs under investigation for the treatment of advanced NSCLC and recommended management.

Released: April 04, 2024

Expiration: April 03, 2025

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.